Development and characterization of mupirocin encapsulated in animal bone-derived hydroxyapatite for management of chronic wounds

Abstract

Background: Hydroxyapatite is an important biomedical material used in drug delivery owing to its excellent bioactivity and biocompatibility. In this study, hydroxyapatite isolated from bovine and caprine bones was capped and used as a drug carrier to encapsulate mupirocin as an active pharmaceutical product in hydrogel formulations which were utilized in wound healing application using animal model (Wistar Rats). Results: Characterization of the mupirocin-encapsulated hydroxyapatite using Fourier transform infrared spectroscopy, and X-ray diffractometer revealed the active presence of mupirocin after encapsulation. The in-vitro drug release study revealed that the capped hydroxyapatite obtained from caprine bone loaded with mupirocin gave drug release rate of 84.67% of the drug within 75 min while conventional mupirocin ointment had the lowest at 27.04% within the same time. The capped hydroxyapatite obtained from bovine bone loaded with mupirocin had the highest encapsulation efficiency of 73.67%. However, the animals treated with formulation prepared from capped hydroxyapatite obtained from caprine bone loaded with mupirocin had the highest wound closure area of 377.8 mm2, while conventional mupirocin ointment had 231.5 mm2 in 16 days of treatment. All the formulations with mupirocin except the ointment showed excellent resistance against Klebsiella pneumonia and Staphylococcus aureus of about 40 mm of inhibition zone. Conclusions: The mupirocin encapsulated in hydroxyapatite extracted from bovine and caprine bones has been demonstrated to be more superior to the conventional ointment in the management of chronic wound conditions.